Compare JEF & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JEF | CRL |
|---|---|---|
| Founded | 1968 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 13.1B |
| IPO Year | 2017 | 1999 |
| Metric | JEF | CRL |
|---|---|---|
| Price | $47.64 | $293.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $61.40 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 1.8M | 827.6K |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | $1,857,601,000.00 |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $10.25 | $3.04 |
| P/E Ratio | $66.06 | ★ N/A |
| Revenue Growth | 2.93 | ★ 10.48 |
| 52 Week Low | $35.53 | $145.47 |
| 52 Week High | $69.93 | $303.31 |
| Indicator | JEF | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 61.22 |
| Support Level | $45.78 | $267.27 |
| Resistance Level | $49.52 | $303.31 |
| Average True Range (ATR) | 1.80 | 9.37 |
| MACD | -0.36 | 0.17 |
| Stochastic Oscillator | 23.84 | 86.35 |
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.